clinical trial · NCT07403188
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Refractory Lupus NephritisMyasthaenia GravisStiff Person SyndromeRheumatoid Arthritis (RA)Multiple SclerosisDermatomyositisSystemic Sclerosis (SSc)KYV-101
brief summary
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
started
Nov 24, 2025
primary completion
Jan 1, 2041
completion
Jan 1, 2041
last updated
Feb 11, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol